
Abionyx Pharma SA
PAR:ABNX

Intrinsic Value
The intrinsic value of one
ABNX
stock under the Base Case scenario is
3.193
EUR.
Compared to the current market price of 1.658 EUR,
Abionyx Pharma SA
is
Undervalued by 48%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Abionyx Pharma SA
Loading...
Fundamental Analysis


Revenue & Expenses Breakdown
Abionyx Pharma SA
Balance Sheet Decomposition
Abionyx Pharma SA
Current Assets | 5.9m |
Cash & Short-Term Investments | 3.2m |
Receivables | 2.3m |
Other Current Assets | 329k |
Non-Current Assets | 7.7m |
PP&E | 2m |
Intangibles | 5.5m |
Other Non-Current Assets | 244k |
Free Cash Flow Analysis
Abionyx Pharma SA
EUR | |
Free Cash Flow | EUR |
Earnings Waterfall
Abionyx Pharma SA
Revenue
|
4.6m
EUR
|
Cost of Revenue
|
-3.7m
EUR
|
Gross Profit
|
844k
EUR
|
Operating Expenses
|
-5.3m
EUR
|
Operating Income
|
-4.5m
EUR
|
Other Expenses
|
84k
EUR
|
Net Income
|
-4.4m
EUR
|
ABNX Profitability Score
Profitability Due Diligence
Abionyx Pharma SA's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

Score
Abionyx Pharma SA's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
ABNX Solvency Score
Solvency Due Diligence
Abionyx Pharma SA's solvency score is 63/100. The higher the solvency score, the more solvent the company is.

Score
Abionyx Pharma SA's solvency score is 63/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ABNX Price Targets Summary
Abionyx Pharma SA
According to Wall Street analysts, the average 1-year price target for
ABNX
is 10.965 EUR
with a low forecast of 10.1 EUR and a high forecast of 12.075 EUR.
Dividends
Current shareholder yield for ABNX is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
ABNX
stock under the Base Case scenario is
3.193
EUR.
Compared to the current market price of 1.658 EUR,
Abionyx Pharma SA
is
Undervalued by 48%.